Rohit K Jain
Overview
Explore the profile of Rohit K Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
849
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Li R, Sexton W, Dhillon J, Berglund A, Naidu S, Borjas G, et al.
Clin Cancer Res
. 2023 Jul;
29(19):3875-3881.
PMID: 37505486
Purpose: Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of durvalumab, a human...
12.
Singh A, Guevara-Patino J, Wang X, Li R, Sonpavde G, Jain R
BioDrugs
. 2023 May;
37(4):505-520.
PMID: 37256534
Antibody-drug conjugates (ADCs) have transformed the treatment landscape in oncology and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs that have been especially successful in clinical...
13.
Rose K, Huelster H, Meeks J, Faltas B, Sonpavde G, Lerner S, et al.
Nat Rev Urol
. 2023 May;
20(7):452.
PMID: 37217696
No abstract available.
14.
Rose K, Huelster H, Meeks J, Faltas B, Sonpavde G, Lerner S, et al.
Nat Rev Urol
. 2023 Mar;
20(7):406-419.
PMID: 36977797
Precision medicine has transformed the way urothelial carcinoma is managed. However, current practices are limited by the availability of tissue samples for genomic profiling and the spatial and temporal molecular...
15.
Davaro F, Davaro E, Rose K, Murthy P, Huelster H, Naidu S, et al.
Urol Oncol
. 2023 Mar;
41(9):389.e7-389.e13.
PMID: 36959058
Objective: Guideline recommendations disagree on template boundaries for pelvic lymph node dissection (PLND) in conventional urothelial carcinoma. Less is known about PLND in variant histology. We aimed to analyze the...
16.
Jain R, Singh A, Wang X, Guevara-Patino J, Sonpavde G
Expert Opin Emerg Drugs
. 2023 Mar;
28(1):17-26.
PMID: 36882977
Introduction: The treatment landscape for advanced-stage, unresectable or metastatic urothelial carcinoma (mUC) has shifted dramatically over a short period of time, with new therapeutic agents available for clinical use. However,...
17.
Tannir N, Agarwal N, Porta C, Lawrence N, Motzer R, McGregor B, et al.
JAMA Oncol
. 2022 Sep;
8(10):1411-1418.
PMID: 36048457
Importance: Dysregulated metabolism is a hallmark of renal cell carcinoma (RCC). Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate. Telaglenastat is an investigational, first-in-class,...
18.
Chakiryan N, Gore L, Reich R, Dunn R, Jiang D, Gillis K, et al.
JAMA Netw Open
. 2022 May;
5(5):e2212347.
PMID: 35576003
Importance: Level I evidence has failed to demonstrate an overall survival (OS) advantage for cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma (ccRCC) in the modern era,...
19.
Adib E, El Zarif T, Jain R, Skelton 4th W, Freeman D, Curran C, et al.
BJUI Compass
. 2022 Feb;
3(2):169-172.
PMID: 35224552
Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in ....
20.
Curran C, Adib E, Kazakova V, Grivas P, Diamantopoulos L, Alva A, et al.
Clin Genitourin Cancer
. 2021 Sep;
20(1):11-16.
PMID: 34503934
Background: Enfortumab vedotin (EV) is approved to treat metastatic urothelial carcinoma (mUC) following platinum and PD1/L1 inhibitors. Since the outcomes and patterns of therapy of patients following discontinuation of EV...